-+ 0.00%
-+ 0.00%
-+ 0.00%

Erasca plans to fund R&D for oncology pipeline with net proceeds from USD 550 million stock offering

PUBT·07/14/2026 03:11:02
Listen to the news
Erasca plans to fund R&D for oncology pipeline with net proceeds from USD 550 million stock offering
  • Erasca mapped out expanded funding plans by raising about $550 million gross in an upsized common stock offering priced at $17.5 a share.
  • Net proceeds will fund R&D for its product candidates, support other development programs, bolster working capital, fund general corporate purposes.
  • Deal targets a July 15, 2026 close; underwriters hold a 30-day option for 4,714,285 additional shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Erasca Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607132310PRIMZONEFULLFEED9761626) on July 14, 2026, and is solely responsible for the information contained therein.